Literature DB >> 2120132

Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.

R Rahner1, A Eckhardt, M Duchêne, H Domdey, B U von Specht.   

Abstract

Two monoclonal antibodies (mAbs) designated 2A1 and 6A4 which had been shown to be directed against Pseudomonas aeruginosa outer membrane lipoprotein I were tested in cyclophosphamide treated mice for their protective ability against P. aeruginosa infection. Pretreatment of mice with either 2 mg of 2A1 or 4 mg of 6A4 in combination with lethally irradiated human leucocytes reduced the mortality after subsequent subcutaneous injection of 100 living P. aeruginosa organisms to 50% of the controls. Without leucocytes only mAb 2A1 (isotype IgG2b) showed protection (47%). Irradiated leucocytes alone without mAb did not protect the mice significantly from fatal P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120132     DOI: 10.1007/bf01643398

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.

Authors:  R E Hancock; L M Mutharia; E C Mouat
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

2.  Intrinsic antibiotic resistance of Pseudomonas aeruginosa.

Authors:  R E Hancock
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

3.  Clinical evaluation of Pseudomonas hyperimmune globulin.

Authors:  C E Jones; J W Alexander; M Fisher
Journal:  J Surg Res       Date:  1973-02       Impact factor: 2.192

4.  Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study.

Authors:  R H Herzig; G P Herzig; R G Graw; M I Bull; K K Ray
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

5.  Mechanisms of lipopolysaccharide-induced protection against pseudomonas sepsis in granulocytopenic mice.

Authors:  B R Tegtmeier; B R Andersen
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

6.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

7.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

8.  Infection following renal transplantation: a changing pattern.

Authors:  H Masur; J S Cheigh; W T Stubenbord
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

9.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho
Journal:  J Gen Microbiol       Date:  1987-12

10.  [Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice].

Authors:  M Trautmann; O Brückner; H Hahn
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1982-07
View more
  1 in total

1.  Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.

Authors:  M Finke; G Muth; T Reichhelm; M Thoma; M Duchêne; K D Hungerer; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.